Mebutamate: Difference between revisions
Kiran Singh (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<div style="float: right;"> | |||
[[File:Mebutamate.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | |||
__NOTOC__ | |||
| | |||
| | |||
| | |||
| | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Mebutamate''' ('''Capla''', '''Dormate''') is an [[anxiolytic]] and [[sedative]] [[drug]] with [[antihypertensive]] effects of the carbamate class.<ref name="TaylorFrancis2000">{{cite book | title = Index Nominum 2000: International Drug Directory | url = http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA634 | date = January 2000 | publisher = Taylor & Francis | isbn = 978-3-88763-075-1 | page = 634}}</ref><ref>{{ cite book | title = The Merck Index | edition = 14 | publisher = Merck Publishers | isbn = 978-0-911910-00-1 | at = 5813 }}</ref> It has effects comparable to those of [[barbiturate]]s such as [[secobarbital]], but is only around 1/3 the potency of secobarbital as a sedative. Side effects include [[dizziness]] and [[headaches]].<ref>{{cite pmid | 6037393}}</ref> | |||
Mebutamate is one of many [[Gabaergic|GABAergic]] drugs which act via [[allosteric]] agonism of the [[GABAA receptor|GABA<sub>A</sub> receptor]] at the β-subreceptor similair to barbiturates. In contrast, [[benzodiazepines]] act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not. | |||
Other carbamates with the same mechanism of action and pharmacological properties include [[meprobamate]], [[carisoprodol]], [[felbamate]], and [[tybamate]]). | |||
== References == | == References == | ||
{{ | {{Reflist|2}} | ||
{{Anxiolytics}} | |||
{{GABAAR PAMs}} | |||
[[Category:Anxiolytics]] | |||
[[Category:Carbamates]] | |||
[[Category:GABAA receptor positive allosteric modulators]] | |||
[[Category:Drug]] | |||
Revision as of 13:49, 7 April 2015
|
WikiDoc Resources for Mebutamate |
|
Articles |
|---|
|
Most recent articles on Mebutamate |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Mebutamate at Clinical Trials.gov Clinical Trials on Mebutamate at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mebutamate
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mebutamate Discussion groups on Mebutamate Patient Handouts on Mebutamate Directions to Hospitals Treating Mebutamate Risk calculators and risk factors for Mebutamate
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mebutamate |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class.[1][2] It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.[3]
Mebutamate is one of many GABAergic drugs which act via allosteric agonism of the GABAA receptor at the β-subreceptor similair to barbiturates. In contrast, benzodiazepines act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not.
Other carbamates with the same mechanism of action and pharmacological properties include meprobamate, carisoprodol, felbamate, and tybamate).
References
- ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. p. 634. ISBN 978-3-88763-075-1.
- ↑ The Merck Index (14 ed.). Merck Publishers. 5813. ISBN 978-0-911910-00-1.
- ↑ PMID 6037393 (PMID 6037393)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand